title: Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
authors.affiliation: Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Sweety
authors.initials: S
authors.lastname: Agrawal
authors.affiliation: Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India yash_deep_gupta@yahoo.co.in.
authors.forename: Yashdeep
authors.initials: Y
authors.lastname: Gupta
mesh_terms: D001713:Biphenyl Compounds; D003924:Diabetes Mellitus, Type 2; D005934:Glucagon; D006801:Humans; D018027:Receptors, Glucagon
chemical_list: D001713:Biphenyl Compounds; D018027:Receptors, Glucagon; C000601762:adomeglivant; D005934:Glucagon